PAOLA-1: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer (Overall Survival) Last updated on Oct 31, 2024 Previous GYOEDU Resident: BRCA, Genetics and Parp Inhibitors Next Publications Update # 79
